Salient Magnetic Resonance Imaging Findings in the Differential Diagnosis of Benign, Borderline and Malignant Ovarian Mucinous Tumors

Overview

Journal Abdom Radiol (NY)

Publisher Springer

Specialties Gastroenterology
Radiology

Date 2024 Aug 26

PMID 39187694

Authors

Safa Ozyilmaz

Fatma Kulali

Cumhur Selcuk Topal

Cem Yalcinkaya

Affiliations

Soon will be listed here.

Abstract

Purpose: In mucinous ovarian tumors, preoperative prediction of histological subgroup is important for treatment approach. Therefore, we aimed to determine salient magnetic resonance imaging (MRI) findings and estimate optimal cut off values for quantitative features in differential diagnosis of benign, borderline and malignant mucinous ovarian tumors.

Methods: Between January 2011 and December 2021, preoperative MRI scans of 50 patients with mucinous ovarian tumors (n = 54) were evaluated retrospectively. MRI findings [size, signal intensity, contrast pattern, features of loculation, wall, septa and mural nodule (MN), diffusion restriction] were investigated. There were benign, borderline, and malignant groups based on histopathological results. The relationship between radiological and histopathological results was analyzed by performing Kruskal Wallis test, Pearson's chi-squared test, receiver operating characteristic analysis.

Results: In our study, there were 54 mucinous ovarian tumors in 50 patients. Of 54, 33 were benign, 13 borderline and eight malignant tumors. In comparison of three groups, tumor size, number of loculation, number and frequency of MN were higher and apparent diffusion coefficient (ADC) value were lower in malignant group (p < 0.05). Septa thickness was lower with optimal cut off value of 2.45 mm in benign group compared to borderline and malignant groups [sensitivity: 79%, specificity: 75%, AUC (Area under the curve): 0.861] (p < 0.05). T2-weighted (T2-w) signal intensity ratio (SIR) of MN was higher in borderline compared to malignant group, with a cut-off value of 3.9 (sensitivity: 85%, specificity: 83%, AUC: 0.943) (p < 0.05). Ascites was also significant in malignant group (p < 0.05).

Conclusion: T2-w SIR of MN with a cut off value of 3.9 is beneficial for differential diagnosis. By awareness of some salient MRI findings (size, septa thickness, number of loculation, number and T2-w SIR of MN, ADC value and ascites), preoperative prediction of histological subgroup of mucinous tumors for appropriate treatment planning is possible.

References

Laurent P, Thomassin-Piana J, Jalaguier-Coudray A . Mucin-producing tumors of the ovary: MR imaging appearance. Diagn Interv Imaging. 2015; 96(11):1125-32. DOI: 10.1016/j.diii.2014.11.034. View

Bent C, Sahdev A, Rockall A, Singh N, Sohaib S, Reznek R . MRI appearances of borderline ovarian tumours. Clin Radiol. 2009; 64(4):430-8. DOI: 10.1016/j.crad.2008.09.011. View

Bazot M, Haouy D, Darai E, Cortez A, Dechoux-Vodovar S, Thomassin-Naggara I . Is MRI a useful tool to distinguish between serous and mucinous borderline ovarian tumours?. Clin Radiol. 2012; 68(1):e1-8. DOI: 10.1016/j.crad.2012.08.021. View

Kim H, Lee S, Shin Y, Park C, Kim K . The Value of Diffusion-Weighted Imaging in the Differential Diagnosis of Ovarian Lesions: A Meta-Analysis. PLoS One. 2016; 11(2):e0149465. PMC: 4764370. DOI: 10.1371/journal.pone.0149465. View

Jeong Y, Outwater E, Kang H . Imaging evaluation of ovarian masses. Radiographics. 2000; 20(5):1445-70. DOI: 10.1148/radiographics.20.5.g00se101445. View

Zhao S, Qiang J, Zhang G, Wang S, Qiu H, Wang L . MRI in differentiating ovarian borderline from benign mucinous cystadenoma: pathological correlation. J Magn Reson Imaging. 2013; 39(1):162-6. DOI: 10.1002/jmri.24083. View

Ohya A, Ichinohe F, Matoba H, Kobara H, Fujinaga Y . Useful preoperative examination findings to classify the grade of ovarian primary mucinous tumor. Abdom Radiol (NY). 2021; 46(6):2393-2402. DOI: 10.1007/s00261-020-02918-4. View

Prat J, DAngelo E, Espinosa I . Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol. 2018; 80:11-27. DOI: 10.1016/j.humpath.2018.06.018. View

Bourdel N, Huchon C, Abdel Wahab C, Azais H, Bendifallah S, Bolze P . Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservation. J Gynecol Obstet Hum Reprod. 2020; 50(1):101966. DOI: 10.1016/j.jogoh.2020.101966. View

10.

Kurnit K, Frumovitz M . Primary mucinous ovarian cancer: options for surgery and chemotherapy. Int J Gynecol Cancer. 2022; 32(11):1455-1462. DOI: 10.1136/ijgc-2022-003806. View

11.

Morgan Jr R, Armstrong D, Alvarez R, Bakkum-Gamez J, Behbakht K, Chen L . Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016; 14(9):1134-63. DOI: 10.6004/jnccn.2016.0122. View

12.

Houck K, Nikrui N, Duska L, Chang Y, Fuller A, Bell D . Borderline tumors of the ovary: correlation of frozen and permanent histopathologic diagnosis. Obstet Gynecol. 2000; 95(6 Pt 1):839-43. DOI: 10.1016/s0029-7844(99)00656-0. View

13.

Bazot M, Nassar-Slaba J, Thomassin-Naggara I, Cortez A, Uzan S, Darai E . MR imaging compared with intraoperative frozen-section examination for the diagnosis of adnexal tumors; correlation with final histology. Eur Radiol. 2006; 16(12):2687-99. DOI: 10.1007/s00330-006-0163-z. View

14.

Song T, Choi C, Kim H, Kim M, Kim T, Lee J . Accuracy of frozen section diagnosis of borderline ovarian tumors. Gynecol Oncol. 2011; 122(1):127-31. DOI: 10.1016/j.ygyno.2011.03.021. View

15.

Mackenzie R, Kommoss S, Winterhoff B, Kipp B, Garcia J, Voss J . Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer. 2015; 15:415. PMC: 4494777. DOI: 10.1186/s12885-015-1421-8. View

16.

Lee Y, Lee M, Ruan A, Chen C, Liu H, Wang C . Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms. Oncotarget. 2016; 7(50):82097-82103. PMC: 5347677. DOI: 10.18632/oncotarget.13449. View

17.

Yang X, Li X, Ma F, Li H, Zhao S, Li Y . MRI characteristics for differentiating mucinous borderline ovarian tumours from mucinous ovarian cancers. Clin Radiol. 2021; 77(2):142-147. DOI: 10.1016/j.crad.2021.10.022. View

18.

Pongsuvareeyakul T, Khunamornpong S, Settakorn J, Sukpan K, Suprasert P, Siriaunkgul S . Accuracy of frozen-section diagnosis of ovarian mucinous tumors. Int J Gynecol Cancer. 2012; 22(3):400-6. DOI: 10.1097/IGC.0b013e31823dc328. View

19.

Okamoto Y, Tanaka Y, Tsunoda H, Yoshikawa H, Minami M . Malignant or borderline mucinous cystic neoplasms have a larger number of loculi than mucinous cystadenoma: a retrospective study with MR. J Magn Reson Imaging. 2007; 26(1):94-9. DOI: 10.1002/jmri.20948. View

20.

Li H, Feng F, Qiang J, Zhang G, Zhao S, Ma F . Quantitative dynamic contrast-enhanced MR imaging for differentiating benign, borderline, and malignant ovarian tumors. Abdom Radiol (NY). 2018; 43(11):3132-3141. DOI: 10.1007/s00261-018-1569-1. View